UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 8-K

Current Report

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~October~~December 293, 2025

AXOGEN, INC.

(Exact Name of Registrant as Specified in Charter)

Minnesota

(State or Other Jurisdiction of

Incorporation or Organization)

001-36046

(Commission File Number)

41-1301878

(I.R.S. Employer Identification No.)

13631 Progress Boulevard, Suite 400 Alachua, Florida

(Address of principal executive offices)

32615

(Zip Code)

(386) 462-6800

(Registrant's telephone number, including area code)

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):


☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e- 4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of exchange on which registered
Common Stock, $0.01 par value	AXGN	The Nasdaq Stock Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition

On October 29, 2025, Axogen, Inc. (the “Company”) issued a press release announcing its third quarter 2025 financial results. A copy of the press release is furnished as Exhibit 99.1.

The information furnished pursuant to Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of such section, nor shall it be incorporated by reference into future filings by the Company under the Securities Act of 1933, as amended (the “Securities Act”), or under the Exchange Act, unless the Company expressly sets forth in such future filing that such information is to be considered “filed” or incorporated by reference therein.

Item 7.01 Regulation FD Disclosure

On ~~October~~December 293, 2025, ~~the~~Axogen, ~~Company~~Inc. ~~posted~~(“Axogen” aor ~~third~~the ~~quarter~~“Company”) ~~2025~~issued ~~financial~~a ~~results~~press ~~presentation~~release toannouncing ~~its~~that ~~website~~the ~~at https://ir~~U.~~axogeninc~~S.~~com/news-events.~~ ~~The~~Food ~~Company~~and ~~may~~Drug ~~use~~Administration (the ~~financial~~“FDA”) ~~results~~has ~~presentation~~approved ~~from~~the ~~time~~Company’s toBiologics ~~time~~License inApplication ~~conversation~~for ~~with~~Avance® ~~analysts,~~(acellular ~~investors,~~nerve ~~and others~~allograft-arwx). ~~A copy of the presentation is furnished as Exhibit 99.2.~~

~~The~~A ~~information~~copy inof ~~this~~the ~~Item~~press ~~7.01,~~release ~~including Exhibit 99.2,~~ is ~~being~~ furnished ~~and~~as ~~shall~~Exhibit ~~not~~99.1 ~~be deemed~~ to bethis ~~“filed”~~Current ~~for~~Report ~~purposes~~on ofForm ~~Section~~8-K ~~18 of the Exchange Act or otherwise subject to the liabilities of that section~~ and ~~shall~~is ~~not be deemed~~ incorporated ~~by reference~~ into ~~any~~this ~~filing~~Item ~~under~~7.01 ~~the Securities Act or Exchange Act, except as shall be expressly set forth~~ by ~~specific~~ reference ~~in such filing~~.

The information in this Item 97.01, including Exhibit 99.1, ~~Financial~~is ~~Statements~~being furnished and ~~Exhibits~~shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section and shall not be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 8.01 Other Events

On December 3, 2025, the Company announced it received FDA approval of its Biologics License Application for Avance® (acellular nerve allograft-arwx). Continued approval for these indications depends on verification and description of clinical benefit in confirmatory studies.

The indications for sensory nerve discontinuities >25 mm and for mixed and motor nerve discontinuities were approved under FDA’s Accelerated Approval pathway based on the effect on static two-point discrimination in sensory nerve gaps ≤25 mm, which provided empirical evidence to reasonably predict clinical benefit given similarities in pathophysiology and anticipated therapeutic effects. Continued approval for these indications depends on verification and description of clinical benefit in confirmatory studies.

Commercial availability of the licensed Avance® product is expected early in the second quarter of 2026. In the meantime, Avance® remains available under the current tissue framework.

Forward-Looking Statements

This Current Report on Form 8-K, including the exhibit furnished herewith, contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding commercial availability of the licensed Avance® (acellular nerve allograft-arwx) product.

Forward-looking statements are based on current expectations and involve risks and uncertainties. Actual results may differ materially from those expressed or implied due to factors such as the timing and outcome of regulatory review, potential delays, requests for additional information by the FDA, and other risks identified in Axogen’ s filings with the SEC.

Axogen undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

Exhibit No.			Description
99.1			Axogen Inc. ~~Earnings~~ Press Release, dated ~~October~~December 293, 2025
99.2			Axogen Inc. Third Quarter Financial Results Presentation, dated October 29, 2025
104			Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	AXOGEN, INC.
Dated: October 29, 2025	By:	/s/ Marc Began
Dated: December 3, 2025	By:	/s/ Marc Began
		Marc Began
		Executive Vice President, General Counsel and Chief Compliance Officer

Filing Compare · Axogen, Inc.